Expertise in
13
conditions

Dr. Daniel E. Kreutz

Rheumatology
Pueblo Pediatrics LTD
2152 S Vineyard Ste 129, 
Mesa, AZ 
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
13
conditions
Pueblo Pediatrics LTD
2152 S Vineyard Ste 129, 
Mesa, AZ 

Overview

Daniel Kreutz is a Rheumatologist practicing medicine in Mesa, Arizona.

Dr. Kreutz is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Arthritis, Rheumatoid Arthritis (RA), Ankylosing Spondylitis, and Axial Spondyloarthritis (AxSpA).

He is actively involved in clinical research, participating in 8 clinical trials. Dr. Kreutz is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in AZ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 27 Less Insurance Carriers -

Locations

Pueblo Pediatrics LTD
2152 S Vineyard Ste 129, Mesa, AZ 85210
Other Locations
Arizona Arthritis and Rheumatology Associates
3645 S Rome St Ste 201, Gilbert, AZ 85297

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required
Before you request

Arizona Arthritis And Rheumatology Associates

4550 E Bell Rd Ste 170, 
Phoenix, AZ 
 (19.6 miles away)
480-443-8400
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nehad Soloman is a Rheumatologist practicing medicine in Phoenix, Arizona. Dr. Soloman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Light Chain Deposition Disease (LCDD), IgG4-Related Disease, and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. Dr. Soloman is currently accepting new patients.

Expertise in
25
conditions
Dr. Areena Swarup
Rheumatology
Expertise in
25
conditions
Dr. Areena Swarup
Rheumatology
Referral required
Before you request

Pueblo Pediatrics LTD

2152 S Vineyard Ste 129, 
Mesa, AZ 
 (0.1 miles away)
480-443-8400
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Areena Swarup is a Rheumatologist practicing medicine in Mesa, Arizona. Dr. Swarup is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Fibromyalgia, Psoriatic Arthritis, and Psoriasis. Dr. Swarup is currently accepting new patients.

Expertise in
37
conditions
Dr. Ravi M. Bhalla
Rheumatology
Expertise in
37
conditions
Dr. Ravi M. Bhalla
Rheumatology
Referral may be required
Before you request

Valley Arthritis Care

13613 W Camino Del Sol Ste 4, 
Sun City West, AZ 
 (36.9 miles away)
623-815-2690
Languages Spoken:
English, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ravi Bhalla is a Rheumatologist practicing medicine in Sun City West, Arizona. Dr. Bhalla is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Palindromic Rheumatism, Fibromyalgia, Rheumatoid Arthritis (RA), and Osteoporosis. Dr. Bhalla is board certified in American Board Of Internal Medicine. Dr. Bhalla is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel E. Kreutz

How do I make an appointment with Dr. Daniel E. Kreutz?

You can book an appointment with Dr. Daniel E. Kreutz by calling their office at 480-443-8400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel E. Kreutz a top-rated expert for Arthritis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel E. Kreutz is classified as an Distinguished expert for Arthritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel E. Kreutz specialize in?

While Dr. Daniel E. Kreutz is a Rheumatology, they have specific expertise in Arthritis, Rheumatoid Arthritis (RA), and Ankylosing Spondylitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Daniel E. Kreutz accept my insurance?

Dr. Daniel E. Kreutz accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 480-443-8400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kreutz's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile